64 CHAPTER 3 Figure 1. PFS and OS in the cohort “Olaparib for tumors with BRCA1/2 mutations”. Kaplan–Meier curves for estimated PFS (left) and OS (right), with 95% CI (dashed lines). Figure 2. Treatment efficacy of olaparib in patients with tumors harboring BRCA1/2 alterations. Swimmer plot of the time on treatment (in weeks) for each patient (n = 27). Patients marked with an arrow were still on treatment (as per November 5th, 2020). On the left side of the figure, the molecular tumor profiles of preenrollment biopsies and DRUP baseline-study biopsies and the histologic tumor types are annotated. NON-BRCA ASSOCIATED HISTOLOGIES Seven patients in this cohort had non-BRCA associated tumor types. Of these, four (57%) had clinical benefit: two patients with cholangiocarcinoma, one with renal cell carcinoma and one with endometrial cancer. WGS data showed bi-allelic LoF of BRCA (Supplementary Table 1). Three patients with non-BRCA associated histologies had no benefit from olaparib. The WGS data from the two patients with colorectal cancer clearly showed no bi-allelic LoF of BRCA and
RkJQdWJsaXNoZXIy MTk4NDMw